Comparative Pharmacology
Head-to-head clinical analysis: DIACOMIT versus DILANTIN 125.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIACOMIT versus DILANTIN 125.
DIACOMIT vs DILANTIN-125
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stiripentol is an anticonvulsant that potentiates GABAergic neurotransmission by acting as a positive allosteric modulator of GABA-A receptors and inhibiting GABA transaminase. It also inhibits CYP2C19 and other cytochrome P450 enzymes, thereby increasing plasma concentrations of concomitant antiepileptic drugs like clobazam.
Phenytoin stabilizes neuronal membranes by promoting voltage-gated sodium channel inactivation, reducing high-frequency neuronal firing and seizure propagation.
10 mg/kg/day orally in two divided doses; increase weekly by 10 mg/kg/day to 70 mg/kg/day or 3 g/day, whichever is lower.
300-400 mg per day orally in divided doses (e.g., 100 mg three times daily); loading dose 1 g orally divided into three doses given at 2-hour intervals, then 100 mg every 6-8 hours for first 24 hours.
None Documented
None Documented
Terminal elimination half-life: 13-20 hours; in severe renal impairment (CrCl <30 mL/min), half-life prolonged to 40-60 hours. Requires dose adjustment.
Terminal half-life: 7-42 hours (mean 22 hours) in adults; dose-dependent due to saturable metabolism. Steady-state reached in 7-10 days.
Primarily renal excretion: 50% as unchanged drug, 30% as glucuronide conjugate, 20% via fecal/biliary routes.
Renal: 70% as metabolites (mainly HPPA glucuronide and sulfate), 5-10% as unchanged drug. Fecal: 30% (minor).
Category C
Category C
Anticonvulsant
Anticonvulsant